PRKAR1A is overexpressed and represents a possible therapeutic target in human cholangiocarcinoma.
about
The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targetsPlasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancerActivated macrophages promote Wnt/β-catenin signaling in cholangiocarcinoma cells.Fatty acid extract from CLA-enriched egg yolks can mediate transcriptome reprogramming of MCF-7 cancer cells to prevent their growth and proliferationPRKAR1A is a functional tumor suppressor inhibiting ERK/Snail/E-cadherin pathway in lung adenocarcinoma.Risk biomarkers for assessment and chemoprevention of liver fluke-associated cholangiocarcinoma.Identification of prostate cancer hub genes and therapeutic agents using bioinformatics approach.Molecular targets in glioblastoma.Targeting protein kinase A in cancer therapy: an update.PKA RIα/A-kinase anchoring proteins 10 signaling pathway and the prognosis of colorectal cancer.Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment.Emerging molecular therapeutic targets for cholangiocarcinoma.STATs profiling reveals predominantly-activated STAT3 in cholangiocarcinoma genesis and progression.Identification of a gene signature for discriminating metastatic from primary melanoma using a molecular interaction network approach.Alternative promoter usage and differential expression of multiple transcripts of mouse Prkar1a gene.Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers.A genetic variation associated with plasma erythropoietin and a non-coding transcript of PRKAR1A in sickle cell disease.PRKAR1A overexpression is associated with increased ECPKA autoantibody in liver fluke-associated cholangiocarcinoma: application for assessment of the risk group.Inhibition of endothelial nitric oxide synthase in cholangiocarcinoma cell lines - a new strategy for therapy.Targeting cholangiocarcinoma.Increased EphB2 expression predicts cholangiocarcinoma metastasis.
P2860
Q26751224-8715A931-D853-4B21-B48A-CF6EFE172352Q35615320-1C34920A-73D7-4E0E-8186-2EF924CCEC12Q36887069-576DC69D-4B07-4F50-8152-063AC8D4E5DDQ37142057-B84383FA-45C3-41F3-99AD-C2E2DC7960A6Q37518538-A53E587E-9BCA-40C1-8584-78F26C64B775Q38177241-79BD78FD-D61B-464F-B254-8D13D631BE20Q38429979-AF243EDF-97DC-47DF-A268-7123F95C78E0Q38465854-892A97E5-633A-4E1A-B4DF-A1653BC23323Q38594971-7EACF6AC-3E24-4004-89E4-84D1E9A96F13Q38957357-93929159-3DE3-476F-8D02-A7AAC1B72869Q39129195-99FDF08C-5C1D-43BD-9082-B146ACDA22CCQ39132926-26C77C2B-DF14-4707-BE88-3A11DCE00B97Q39227356-758772FB-995C-48C6-AD18-36C3744ABC73Q45011155-E4BA2149-4F0F-4EB6-80F3-5F036A08A939Q45943042-247FEF55-9C59-4E2E-8DE2-CB8FC5C0CCAAQ48057741-A7A5D242-F433-49C6-8102-0CDCFEED22EBQ50127508-40F957C8-4A30-4614-831E-2665CF6D2EC1Q51148340-3CE58CF9-C9C3-4E5C-A1CD-626ABA9AD385Q51757210-E67093A4-410A-4D35-A22B-D858DCAD955FQ52597485-5034F53B-31BA-49B5-9A67-2FFA930B94A8Q52757760-F9C7B99C-2402-4848-9BE3-E2C8A2630D13Q54338851-4B3AC23C-BCFA-4CE4-AEFB-FE7C8CDDB179
P2860
PRKAR1A is overexpressed and represents a possible therapeutic target in human cholangiocarcinoma.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
PRKAR1A is overexpressed and r ...... t in human cholangiocarcinoma.
@en
PRKAR1A is overexpressed and r ...... t in human cholangiocarcinoma.
@nl
type
label
PRKAR1A is overexpressed and r ...... t in human cholangiocarcinoma.
@en
PRKAR1A is overexpressed and r ...... t in human cholangiocarcinoma.
@nl
prefLabel
PRKAR1A is overexpressed and r ...... t in human cholangiocarcinoma.
@en
PRKAR1A is overexpressed and r ...... t in human cholangiocarcinoma.
@nl
P2093
P2860
P50
P356
P1476
PRKAR1A is overexpressed and r ...... t in human cholangiocarcinoma.
@en
P2093
Anucha Puapairoj
Gregory J Riggins
Hideyuki Saya
Masanao Miwa
Nisana Namwat
Sirinun Juntana
Vajarabhongsa Bhudhisawasdi
P2860
P356
10.1002/IJC.25646
P577
2010-11-03T00:00:00Z